# 1. Financial Performance ## A. Key Figures * **Operating EBITDA:** **₹1,356 Cr** Q4 FY26 (+41%) · **16%** Full Year FY26 growth ## B. Margin Trajectory & Profitability * **Core Business Resilience:** Base business performance (ex-acquisition) remains robust, with revenue and EBITDA growth tracking in line with full-year averages while maintaining steady margins. * **Acquisition Integration:** Post-merger margin trajectory has outperformed internal management expectations; reported figures include **ESOP costs**, though press release metrics exclude them for clarity. * **Exceptional Items & Accounting:** Quarterly results were impacted by **INR 65 Cr** in one-time charges related to both Torrent and JB Pharma; current depreciation levels are now set as the baseline for FY27. * **R&D Investment:** Research spending remains disciplined at **5%** of sales, with a planned **0.5%** incremental step-up to support pipeline development in India and the US. --- # 2. India Business Performance ## A. Key Figures * **India Revenue:** **₹2,215 Cr** Q4 Total (+43%) · **15%** Base Business Growth * **Market Outperformance:** **3.8%** Volume Growth (vs 1.7% IPM) · **6.7%** Price Growth (vs 5.5% IPM) * **Semaglutide Sales:** **₹17 Cr** April Total (₹11 Cr Injectable / ₹6 Cr Oral) * **Field Force:** **7,100** Current Personnel · **7,500** FY27 Target ## B. Chronic Segment Growth * **IPM Outperformance:** Base business growth significantly exceeded the Indian Pharmaceutical Market (IPM) average, driven by superior volume, pricing, and new product contributions. * **First-to-Market Strategy:** Strengthened CNS and psychiatry portfolios via the first generic launch of **Brexpiprazole**; future growth anchored by a robust R&D pipeline and the upcoming **NASH product** launch. * **NASH Contribution:** Management expects the upcoming Nonalcoholic Steatohepatitis (NASH) therapy to add **1% to 2%** to total India growth within two years of launch. ## C. Semaglutide Launch Metrics * **Dominant Market Entry:** The generic Semaglutide launch (Semalix/Sembolic) is the company's most successful to date, with projected annual sales of **₹200–250 Cr**, tripling the first-year performance of Sitagliptin. * **Early Mover Advantage:** Despite new competition, Torrent maintains a majority share due to a two-month head start and a comprehensive portfolio including oral formats and multiple injectable delivery systems (pens/cartridges). * **Margin Trajectory:** Current EBITDA margins for the franchise are suppressed by launch expenses and high third-party API costs; however, a margin reversal is expected by next year as the product scales toward base business profitability. * **Supply & Manufacturing:** While currently using manufacturing partners, Torrent is evaluating a shift to **in-house production** for injectables if scale warrants; minor supply tightness in low-dosage SKUs is not expected to impact market share. ## D. Curatio Integration & Sales Force Expansion * **Curatio Momentum:** The segment delivered robust double-digit growth in FY26, fueled by aggressive OTC advertising and strategic field force expansion. * **Field Force Optimization:** Plans to cap the medical representative count at **7,500** by FY27, followed by the full integration of the JB Pharma team to maximize productivity without further headcount increases. --- # 3. International Market Mix ## A. Brazil Branded Generics * **Market Outperformance:** Robust double-digit constant currency growth exceeded broader market trends, supported by a significant pipeline of **58 molecules** awaiting ANVISA approval. * **Strategic GLP-1 Positioning:** Management is targeting the **USD 1 billion** Semaglutide market; filings are complete in 4-5 markets with "Wave 1" launch expectations as patients transition from Ozempic to Wegovy. [9, 10] * **Margin Resilience:** High gross margins in branded generics allow the company to absorb an **8% customs duty** on finished products, a rate significantly lower than previous analyst estimates. [9, 10] * **Portfolio Expansion:** Growth is increasingly driven by new launches in high-value segments, including the company's first oncology product and a rosuvastatin/ezetimibe combination holding an **8.5% market share**. [3, 11] ## B. Germany Tender Business * **Supply Chain Headwinds:** Slight constant currency contraction was primarily due to third-party supplier disruptions rather than underlying demand shifts. * **Conservative Outlook:** Management projects modest low single-digit growth (under 5%) for the upcoming fiscal year as the business stabilizes. ## C. US Generic Portfolio * **Launch-Led Momentum:** Strong top-line growth driven by new products reaching target share and volume expansion in the base portfolio. * **Path to Full Profitability:** Currently profitable pre-R&D; management is optimizing the cost structure to achieve net profitability, supported by a **single-digit number of launches** over the next **9-10 months**. [7, 12] ## D. European Biosimilar Strategy * **Regulatory Pivot:** Capitalizing on German regulatory shifts allowing automatic biosimilar substitution; the business is transitioning to a tender-based model effective **April 2026**. [4, 16] * **Early-Stage Scaling:** While current sales from the first partner-led biosimilar launch are immaterial, upcoming tenders in **June-July** will serve as a critical litmus test for competitive positioning. * **Supply Chain Strategy:** Actively seeking global partnerships, particularly with **Asian manufacturers**, to ensure cost competitiveness in a declining price environment. --- # 4. M&A & Synergy Progress ## A. Key Figures * JB Pharma Net Impact: **-₹195 Cr** Net adjustment (Amortization of **₹257 Cr** less **₹62-63 Cr** DTL reversal) * **Cost Synergy Guidance:** **₹400–450 Cr** Total by Year 3 · **20%** Year 1 target ## B. JB Pharma Integration * **Consolidation & Accounting:** Financials now reflect the controlling stake acquired on **January 21, 2026**, with the adjusted net loss allocated between non-controlling interest (**51.2%**) and owners' equity (**48.8%**). * **Operational Stabilization:** Business discontinuations implemented in Q4 are now finalized with no further cuts planned; sales force attrition has successfully dropped to below-industry averages. * **Workforce Targets:** Management aims to further reduce sales force turnover to align with the base business's **high single-digit** attrition rate by next year. ## C. Cost Synergy Realization * **Accelerated Execution:** Integration is tracking ahead of the internal synergy plan, with margin trajectories exceeding initial expectations due to earlier-than-anticipated cost removals. * **Phasing Outlook:** While the **20-60-20** percent phasing over FY27–FY29 remains the formal guide, management signaled potential for front-loaded benefits in the first year. * **Revenue Synergies:** Top-line benefits are not expected to be material in the current fiscal year but carry high management confidence for the **two-to-three-year** horizon. ## D. NCLT Approval & Future Deals * **Merger Finalization:** The JB Pharma merger has secured shareholder approval and is in the final stage, awaiting an NCLT hearing scheduled for **next month**. * **Business Development:** Active exploration of in-licensing opportunities is underway, specifically targeting discussions with multiple **Chinese firms** to bolster the portfolio. --- # 5. R&D & Pipeline Progress ## A. Pipeline & Operational Metrics * **NASH Launch Timeline:** **12 to 18 months** post-patent expiry * **ANVISA Pipeline:** **58 products** currently under review * **Launch Capacity:** **~6 products** per year (2 products per team across 3 teams) ## B. NASH Product Development * **First-to-Market Ambition:** Torrent is conducting Phase 3 trials for Resmetirom, aiming for a first-mover advantage in India to capture a significant market opportunity. * **Strategic Resource Allocation:** R&D funding is being pivoted from international markets toward the India business to maintain a stable net spend while fueling domestic growth. * **Leveraging Infrastructure:** Management intends to utilize its existing Medical Representative (MR) base to scale high-potential therapeutic areas like NASH. ## C. Oncology & Metabolic Portfolio * **Oncology Expansion:** The company is actively evaluating product opportunities sourced from **China** to broaden its oncology footprint. * **GLP-1 Strategy:** The Ozempic file is under ANVISA review with an aim to be a top-five player at launch; Wegovy submission is currently in development. * **Manufacturing Integration:** Oral Semaglutide was developed and manufactured in-house, though the company currently relies on third-party API sourcing. --- # 6. Pricing & Regulatory Risks ## A. API Cost Escalations & Pricing Strategy * **Strategic Price Reduction:** Management lowered oral Semaglutide pricing following a significant drop in API costs, moving away from expensive early-procurement levels. * **Margin Expansion Outlook:** Gross margins for oral formats currently trail injectables but are projected to reach high levels as input costs continue to deflate. * **Pricing Stability:** No further price cuts are anticipated for oral tablets, and management intends to maintain stable pricing for the injectable portfolio. * **External Risk Factors:** Potential headwinds to domestic and international performance include raw material volatility linked to Middle East geopolitical tensions. ## B. ANVISA Substitution Rules * **Regulatory Tightening in Brazil:** ANVISA has adopted a strict stance on Ozempic substitution for weight loss following the Wegovy launch, causing a rapid decline in off-label sales. * **Generic Market Entry:** No generic Semaglutide versions have secured approval in Brazil to date, as the regulator continues to reject or review all pending applications. * **Market Alignment:** Product pricing is expected to follow standard Indian Pharmaceutical Market (IPM) trajectories despite aggressive competitor entry points. ## C. CDMO Business Volatility * **International Headwinds:** The JB Pharma CDMO segment is facing pressure from a change of control, business realignment, and ongoing geopolitical instability in the Middle East. --- # 7. Guidance & Outlook ## A. FY27 Revenue Targets * **Accelerating Organic Momentum:** Management expects the base business to outpace previous year’s growth rates, contingent on a stable geopolitical environment. * **India Growth Drivers:** Domestic performance is anchored by chronic segment outperformance and high-impact launches, specifically **Semaglutide**. ## B. Brazil Market Projections * **Steady Latin American Expansion:** Top-line guidance for Brazil remains robust through FY28, reflecting confidence in regional market penetration. ## C. US Launch Calendar * **Device Volume Uncertainty:** Management maintains a cautious stance on drug device volumes (pens/injectors) for **2027-2029**, citing unpredictable competitive dynamics.